| PMID,Country,Sample size,Median age (range),Sex (Male/Female),Lines of Prior treatment,Autologous stem cell transplantation before Chimeric antigen receptor-T,Lymphodepletion,Antigen,CAR construct: vector/costimulatory molecule/single-chain fragment variable species,T cell origin,T cell subset,B cell maturation antigen positivity requirement at enrollment,Chimeric antigen receptor-T dose,Follow-up | |
| 29812997,Western,26,18-70,13/13,10 (3-19),85%,Fludarabine/Cyclophosphamide: 30mg/m2/300mg/m2 daily on day -5 to -3,B cell maturation antigen,γ-retrovirus/CD28/murine,Autologous,CD4/CD8,>50%,0.3-9.0x106/Kg,Median 20 weeks | |
| 30572922,Eastern,57,54 (27-72),34/23,3 (1-9),18%,Cyclophosphamide:300 mg/m2 on day -5 to -3,B cell maturation antigen,Lentivirus/4-1BB/Llama,Autologous,Unselected,Required (cutoff not reported),Median 0.5 (0.07-2.1)x106/Kg,Median 32 (2.8-82.8) weeks | |
| 31042825,Western,33,60 (37-75),21/12,7 (3-23),97%,Fludarabine/Cyclophosphamide: 30mg/m2/300mg/m2 daily on day -5 to -3,B cell maturation antigen,Lentivirus/4-1BB/murine,Autologous,CD4/CD8,Dose-escalation: ≥50%; dose-expansion: not reported,50-800x106,Median 45 (24.8-91.2) weeks | |
| 30988175,Eastern,17,55 (35-73),11/6,5 (3-11),47%,Fludarabine/Cyclophosphamide: 25 mg/m2 daily for 3 days/250/300mg/m2,B cell maturation antigen,Lentivirus/4-1BB/Llama,,CD4/CD8,Required (cutoff not reported),0.21-1.52x106/Kg,Median 60 (1.7-76.4) weeks | |
| 30896447,Western,25,58 (44-75),17/8,7 (3-13),92%,Cyclophosphamide: 1.5g/m2 or no Lymphodepletionmphodepletion,B cell maturation antigen,Lentivirus/4-1BB/human,Autologous,CD4/CD8,Not required,1-50x107,Median 54 weeks | |
| 30830874,Western,10,61 (48-68),4/6,6 (2-10),100%,Melphalan: 140-200 mg/m2,CD19,Lentiviral/4-1BB,Autologous,Unselected,not reported,1-5x107,>14 weeks | |
| 27270177,Western,8,56.5 (43-69),3/5,,,,κ light chain,Retroviral/CD28/murine,Autologous,CD4/CD8,not reported,0.2-2x108/m2,(6-96) weeks | |
| 30396908,Western,5,70 (44-79),3/2,≥5,100%,No Lymphodepletion,NKG2D-ligands,γ-retroviral/NKG2D-CAR,Autologous,CD4/CD8,not reported,1x106-3×107,(14-107) weeks | |
| 31378662,Eastern,21,58 (49.5-61),not available,6 (5-8),14%,Fludarabine/Cyclophosphamide: 30mg/m2 for 3 days /750mg/m2 daily for 1 day,CD19 and B cell maturation antigen,Lentiviral/4-1BB/human (anti-CD19) murine (anti-B cell maturation antigen),Autologous,Unselected,not reported,CD19(1×10^6/Kg) B cell maturation antigen (1×10^6/Kg),Median 25.6 (10.3-42.1) weeks | |